Drug Trial Radar · NCT05728944
Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
229
Actual
Start
Mar 6, 2023
Primary completion
Dec 14, 2023
Study completion Jan 24, 2024
Sponsor
- Lead sponsor
- LENZ Therapeutics, IncAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia
Conditions
- Presbyopia
- Near Vision
- Refractive Error
- Eye Diseases
Interventions
Aceclidine+Brimonidine combination ophthalmic solutionDrug
Aceclidine + Brimonidine combination ophthalmic solution
Aceclidine ophthalmic solutionDrug
Aceclidine ophthalmic solution
VehicleDrug
Proprietary vehicle ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance VisionTime frame: 3 hours post-treatment in the study eye on Day 1
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Site #209
Dothan, Alabama
Site #216
Scottsdale, Arizona
Site #220
Glendale, California
Site #214
La Jolla, California
Site #203
Newport Beach, California
Site #204
Danbury, Connecticut
Site #205
Crystal River, Florida
Site #218
Northbrook, Illinois
Site #211
Louisville, Kentucky
Site #208
St Louis, Missouri
Site #215
Bozeman, Montana
Site #219
Dover, New Jersey
Site #221
Rochester, New York
Site #212
West Fargo, North Dakota
Site #207
Powell, Ohio
Site #213
Eugene, Oregon
Site #217
Warwick, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.